Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (446) 446
Publication (72) 72
Book / eBook (11) 11
Patent (6) 6
Book Chapter (4) 4
Dissertation (2) 2
Streaming Video (2) 2
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Government Document (1) 1
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (188) 188
index medicus (136) 136
hematology (116) 116
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (96) 96
imatinib mesylate (85) 85
chronic myelogenous leukemia (81) 81
oncology (79) 79
benzamides (73) 73
leukemia, myelogenous, chronic, bcr-abl positive - genetics (61) 61
chronic myeloid-leukemia (60) 60
hemic and lymphatic diseases (57) 57
fusion proteins, bcr-abl - genetics (56) 56
female (53) 53
animals (52) 52
chronic myeloid leukemia (51) 51
male (51) 51
mutation (51) 51
antineoplastic agents - therapeutic use (48) 48
bcr-abl (47) 47
imatinib (46) 46
protein kinase inhibitors - therapeutic use (46) 46
middle aged (44) 44
adult (43) 43
mice (42) 42
pyrimidines - therapeutic use (42) 42
aged (41) 41
protein kinase inhibitors - pharmacology (41) 41
leukemia (40) 40
piperazines - therapeutic use (40) 40
pyrimidines - pharmacology (40) 40
piperazines - pharmacology (37) 37
fusion proteins, bcr-abl - antagonists & inhibitors (35) 35
article (33) 33
dasatinib (33) 33
treatment outcome (33) 33
antineoplastic agents - pharmacology (32) 32
drug resistance, neoplasm (31) 31
leukemia, myelogenous, chronic, bcr-abl positive - pathology (31) 31
protein-tyrosine kinases - antagonists & inhibitors (31) 31
tyrosine kinase (30) 30
cml (29) 29
drug therapy (29) 29
fusion proteins, bcr-abl - metabolism (29) 29
abridged index medicus (28) 28
cancer (27) 27
cell line, tumor (27) 27
research (27) 27
therapy (27) 27
acute lymphoblastic-leukemia (26) 26
analysis (25) 25
drug resistance, neoplasm - genetics (25) 25
chronic-phase (24) 24
genetic aspects (24) 24
philadelphia-chromosome (24) 24
aged, 80 and over (21) 21
tyrosine kinase inhibitor (21) 21
blast crisis (20) 20
interferon-alpha (20) 20
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (20) 20
cytogenetic responses (19) 19
hematology, oncology and palliative medicine (19) 19
nilotinib (19) 19
prognosis (19) 19
resistance (19) 19
tyrosine (19) 19
clinical resistance (18) 18
follow-up (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (18) 18
mutations (18) 18
neoplasms (17) 17
philadelphia chromosome (17) 17
protein structure, tertiary (17) 17
care and treatment (16) 16
fusion proteins, bcr-abl (16) 16
pyrimidines - administration & dosage (16) 16
antineoplastic agents - administration & dosage (15) 15
apoptosis (15) 15
cell biology (15) 15
dose-response relationship, drug (15) 15
patients receiving imatinib (15) 15
piperazines - administration & dosage (15) 15
acute myeloid-leukemia (14) 14
apoptosis - drug effects (14) 14
fusion proteins, bcr-abl - chemistry (14) 14
inhibitor (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (14) 14
myeloid neoplasia (14) 14
protein-tyrosine kinases - genetics (14) 14
proteins (14) 14
stem-cells (14) 14
antineoplastic agents (13) 13
follow-up studies (13) 13
health aspects (13) 13
k562 cells (13) 13
kinase domain mutations (13) 13
medicine (13) 13
medicine, research & experimental (13) 13
patients (13) 13
phosphorylation (13) 13
protein kinase inhibitors - administration & dosage (13) 13
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Online Resources - Online (2) 2
Engineering & Comp. Sci. - Stacks (1) 1
Robarts - Reference (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trinity College (John W Graham) - Reference (1) 1
Trinity College (John W Graham) - Storage (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
by Yan, Dongqing and Pomicter, Anthony D and O'Hare, Thomas and Deininger, Michael W
Clinical Cancer Research, ISSN 1078-0432, 11/2019, Volume 25, Issue 22, pp. 6561 - 6563
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
by Eide, Christopher A and Zabriskie, Matthew S and Savage Stevens, Samantha L and Antelope, Orlando and Vellore, Nadeem A and Than, Hein and Schultz, Anna Reister and Clair, Phillip and Bowler, Amber D and Pomicter, Anthony D and Yan, Dongqing and Senina, Anna V and Qiang, Wang and Kelley, Todd W and Szankasi, Philippe and Heinrich, Michael C and Tyner, Jeffrey W and Rea, Delphine and Cayuela, Jean-Michel and Kim, Dong-Wook and Tognon, Cristina E and O'Hare, Thomas and Druker, Brian J and Deininger, Michael W
Cancer Cell, ISSN 1535-6108, 10/2019, Volume 36, Issue 4, pp. 431 - 443.e5
BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph ) leukemia is effectively... 
targeted therapy | ABL001 | chronic myeloid leukemia | allosteric inhibitors | ponatinib | compound mutation | asciminib | CHRONIC PHASE | STEM-CELLS | CML | ONCOLOGY | BCR-ABL | IMATINIB | CLINICAL RESISTANCE | COMPOUND MUTATIONS | MECHANISMS | NILOTINIB | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | Tyrosine | Medical colleges | Gene mutations | Drug approval | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pregnancy Outcomes in Patients Treated with Bosutinib
by Cortes, Jorge E and Gambacorti-Passerini, Carlo and Deininger, Michael W and Abruzzese, Elisabetta and DeAnnuntis, Liza and Brümmendorf, Tim H
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1729 - 1729
Abstract Introduction: Studies in animals have shown reproductive toxicity with bosutinib exposure, with teratogenic events in maternal exposure, but little is... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
by Zhang, HJ and Wilmot, B and Bottomly, D and Dao, KHT and Stevens, E and Eide, CA and Khanna, V and Rofelty, A and Savage, S and Schultz, AR and Long, N and White, L and Carlos, A and Henson, R and Lin, CW and Searles, R and Collins, RH and DeAngelo, DJ and Deininger, MW and Dunn, T and Hein, T and Luskin, MR and Medeiros, BC and Oh, ST and Pollyea, DA and Steensma, DP and Stone, RM and Druker, BJ and McWeeney, SK and Maxson, JE and Gotlib, JR and Tyner, JW
BLOOD, ISSN 0006-4971, 09/2019, Volume 134, Issue 11, pp. 867 - 879
Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are... 
GENE-MUTATIONS | NEOPLASMS | RAS | JUVENILE MYELOMONOCYTIC LEUKEMIA | MOLECULAR PATHOGENESIS | CLASSIFICATION | MDS/MPN | HEMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)
by Eisenwort, Gregor and Keller, Alexandra and Willmann, Michael and Sadovnik, Irina and Georg, Greiner and Gleixner, Karoline V and Ivanov, Daniel and Berger, Daniela and Stefanzl, Gabriele and Winding, Christiana and Hoermann, Gregor and Sperr, Wolfgang R and Sill, Heinz and Bettelheim, Peter and Geissler, Klaus and Deininger, Michael W and Rülicke, Thomas and Valent, Peter
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4223 - 4223
Chronic myelomonocytic leukemia (CMML) is a stem cell-derived hematopoietic neoplasm characterized by dysplasia, uncontrolled expansion of monocytic... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
by Yan, DQ and Pomicter, AD and Tantravahi, S and Mason, CC and Senina, AV and Ahmann, JM and Wang, Q and Than, H and Patel, AB and Heaton, WL and Eiring, AM and Clair, PM and Gantz, KC and Redwine, HM and Swierczek, SI and Halverson, BJ and Baloglu, E and Shacham, S and Khorashad, JS and Kelley, TW and Salama, ME and Miles, RR and Boucher, KM and Prchal, JT and O'Hare, T and Deininger, MW
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2019, Volume 25, Issue 7, pp. 2323 - 2335
Purpose: Myelofibrosis is a hematopoietic stem cell neoplasm characterized by bone marrow reticulin fibrosis, extramedullary hematopoiesis, and frequent... 
POLYCYTHEMIA-VERA | MYELOPROLIFERATIVE NEOPLASMS RESEARCH | KPT-330 INHIBITOR | ONCOLOGY | PRECLINICAL MODELS | STRUCTURAL BASIS | TYROSINE KINASE JAK2 | SELECTIVE INHIBITORS | ESSENTIAL THROMBOCYTHEMIA | EUROPEAN LEUKEMIANET ELN | AVAILABLE THERAPY | myeloproliferative neoplasms | XPO1 | SINE | CRM1 | nuclear export | RAN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
by Cortes, Jorge E and Gambacorti-Passerini, Carlo and Deininger, Michael W and Mauro, Michael J and Chuah, Charles and Kim, Dong-Wook and Milojkovic, Dragana and le Coutre, Philipp and Garcia-Gutierrez, Valentin and Crescenzo, Rocco and Mamolo, Carla and Reisman, Arlene and Hochhaus, Andreas and Brümmendorf, Tim H and BFORE Study Investigators and the BFORE Study Investigators
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 6/2019, Volume 145, Issue 6, pp. 1589 - 1599
In the phase 3 BFORE trial (NCT02130557), treatment with bosutinib resulted in a significantly higher major molecular response rate at 12 months versus... 
Health-related quality of life | Imatinib | Medicine & Public Health | Hematology | Oncology | Cancer Research | Internal Medicine | Chronic myeloid leukemia | Patient-reported outcomes | Bosutinib | FUNCTIONAL ASSESSMENT | CANCER-THERAPY | ADHERENCE | RESISTANT | GENERAL-POPULATION | INTERFERON | INTOLERANT | ONCOLOGY | LOW-DOSE CYTARABINE | SKI-606 | QUALITY-OF-LIFE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience
by Signorelli, Jason and Ravulapati, Sowmya and Patel, Jay L and Deininger, Michael W and Tantravahi, Srinivas K
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4315 - 4315
Abstract Introduction: Langerhans cell histiocytosis (LCH) is a clonal neoplastic disorder of CD1a/CD207 positive myeloid dendritic cells with broad clinical... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective
by Than, Hein and Qiao, Yi and Huang, Xiaomeng and Yan, Dongqing and Khorashad, Jamshid S and Pomicter, Anthony D and Kovacsovics, Tibor J and Marth, Gabor T and O’Hare, Thomas and Deininger, Michael W
Leukemia, ISSN 0887-6924, 09/2018, Volume 32, Issue 9, pp. 2049 - 2054
Genome-Wide Association Study | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Leukemia, Myelomonocytic, Chronic - mortality | Clonal Evolution - genetics | Biomarkers, Tumor | Leukemia, Myelomonocytic, Chronic - drug therapy | Genetic Heterogeneity | Whole Exome Sequencing | Models, Biological | Decitabine - pharmacology | Polymorphism, Single Nucleotide | Leukemia, Myelomonocytic, Chronic - pathology | DNA Methylation - drug effects | Decitabine - therapeutic use | Antimitotic agents | Usage | Prognosis | Gene mutations | Chronic myelomonocytic leukemia | Exome sequencing | Stem cells | Genetic aspects | Transplantation | Research | Antineoplastic agents | Myelomonocytic leukemia | Leukemia | Computer applications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera
by Patel, Ami B and Franzini, Anca and Leroy, Emilie and Kim, Soo Jin and Pomicter, Anthony D and Genet, Lidvine and Xiao, Michael and Yan, Dongqing and Ahmann, Jonathan and Agarwal, Archana M and Clair, Phillip and Addada, Juanah and Lambert, Jonathan and Salmon, Matthew and Gleich, Gerald J and Cross, Nicholas CP and Constantinescu, Stefan and O'Hare, Thomas and Prchal, Josef T and Deininger, Michael W
Blood, ISSN 0006-4971, 10/2019
Key Points A novel insertion/deletion mutation in JAK2 is associated with eosinophilia and erythrocytosis, possibly representing a new clinical entity. JAK2... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling
by Franzini, Anca and Khorashad, Jamshid S and Than, Hein and Pomicter, Anthony D and Yan, Dongqing and O'Hare, Thomas and Deininger, Michael W
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3889 - 3889
Abstract Chronic myelomonocytic leukemia (CMML) is a genetically heterogeneous hematopoietic stem cell disorder that combines features of a myelodysplastic... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
by Cortes, Jorge E and Cortes, Jorge E and Apperley, Jane F and Apperley, Jane F and DeAngelo, Daniel J and Deangelo, Daniel J and Deininger, Michael W and Deininger, Michael W and Kota, Vamsi K and Kota, Vamsi K and Rousselot, Philippe and Rousselot, Philippe and Gambacorti-Passerini, Carlo and Gambacorti-Passerini, Carlo
Journal of hematology & oncology, ISSN 1756-8722, 12/2018, Volume 11, Issue 1, pp. 143 - 12
Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic... 
Dosing strategies | Chronic myeloid leukemia | Adverse events | Tyrosine kinase inhibitor | Bosutinib | EFFICACY | SAFETY | HEART-FAILURE | INTOLERANCE | NILOTINIB | TYROSINE KINASE INHIBITORS | 2013 ACCF/AHA GUIDELINE | TASK-FORCE | ONCOLOGY | IMATINIB | RESISTANCE | HEMATOLOGY | Complications and side effects | Patient outcomes | Dosage and administration | Research | Drug therapy | Leukemia | Prophylaxis | Multiple myeloma | Cardiovascular disease | Regulatory approval | Cardiology | Protein-tyrosine kinase | Chromosomes | Heart failure | Tyrosine | Thrombocytopenia | Task forces | Alanine | Myeloid leukemia | Diarrhea | Nausea | FDA approval | Management | Patients | Disease prevention | Intolerance | Response rates | Alanine transaminase | Lymphomas | Aspartate aminotransferase | Clinical medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial
by Mauro, Michael J and Cortes, Jorge E and Kantarjian, Hagop M and Shah, Neil P and Bixby, Dale L and Flinn, Ian W and O'Hare, Thomas and Rivera, Victor M and Lustgarten, Stephanie and Santillana, Sergio and Heinrich, Michael C and Druker, Brian J and Deininger, Michael W and Talpaz, Moshe
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 3063 - 3063
Abstract Background: Ponatinib, an oral tyrosine kinase inhibitor with potent activity against native and mutant BCR-ABL1, is approved for patients with... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia
by Broadbent, Tyson and Tantravahi, Srinivas K and Ravulapati, Sowmya and Ward, Morgan and Asay, Alexandra and Peddinti, Ananth and Kunz, Isaac and Shami, Paul J and Kovacsovics, Tibor and Courdy, Samir and Boucher, Ken and Deininger, Michael W
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5521 - 5521
Abstract Introduction:Chronic myelomonocytic leukemia (CMML) is a genetically heterogeneous myeloid neoplasm characterized by the presence of both dysplastic... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia
by Antelope, Orlando and Vellore, Nadeem A and Pomicter, Anthony D and Patel, Ami B and Van Scoyk, Alexandria and Clair, Phillip M and Deininger, Michael W and O'Hare, Thomas
Experimental Hematology, ISSN 0301-472X, 09/2019, Volume 77, pp. 36 - 40.e2
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the cornerstone of treatment in chronic myeloid leukemia. Although there are now four TKIs approved for use in... 
MEDICINE, RESEARCH & EXPERIMENTAL | BCR/ABL | HEMATOLOGY | IMATINIB | CHRONIC MYELOID-LEUKEMIA | PARKINSONS-DISEASE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. CML
: genetic paradigm of targeted therapy, part 1 of 2
by Deininger, Michael W
2015, Cancer genetics
Translocation, Genetic | Drug delivery systems | drug therapy | methods | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | imatinib | drug effects | Chronic myeloid leukemia | Antineoplastic agents | Molecular Targeted Therapy | antagonists & inhibitors | Protein Kinase Inhibitors | Inhibitors | genetics | Fusion Proteins, bcr-abl | pharmacology | Genetic aspects | Protein-Tyrosine Kinases | Protein kinases | Philadelphia Chromosome | Cancer
Web Resource
Details down arrow
17. CML
: genetic paradigm of targeted therapy, part 2 of 2
by Deininger, Michael W
2015, Cancer genetics
Drug delivery systems | drug therapy | methods | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | imatinib | Chronic myeloid leukemia | Antineoplastic agents | Neoplasms | antagonists & inhibitors | Protein Kinase Inhibitors | Inhibitors | genetics | Fusion Proteins, bcr-abl | Genetic aspects | Protein-Tyrosine Kinases | Protein kinases | therapeutic use | Cancer
Web Resource
Details down arrow
18. Part 1: Targeting cancer pathways: Tumor resistance
by Yaffe, Michael B and Engelman, Jeffrey and Deininger, Michael W
Science, ISSN 0036-8075, 10/2014, Volume 346, Issue 6207, pp. 369 - 369
This webinar is the first in a series focusing on the pathways that allow for cancer development and progression, the emerging research in identifying and... 
Mutations | Progressions | Pathways | Genetics | Evolution | Survival | Tumors | Cancer
Journal Article
Details down arrow
19. Full Text Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey
by George, Gemlyn and Atallah, Ehab L and Mauro, Michael J and Goldberg, Stuart L and Baim, Arielle and Guhl, Jessica and Hinman, Alexander and Cortes, Jorge E and Deininger, Michael W and Druker, Brian J and Kota, Vamsi K and Larson, Richard A and Lipton, Jeffrey H and Moore, Joseph O and Oehler, Vivian G and Pinilla Ibarz, Javier and Radich, Jerald and Ritchie, Ellen K and Schiffer, Charles A and Shah, Neil P and Silver, Richard T and Sweet, Kendra L and Thompson, James E and Wadleigh, Martha and Flynn, Kathryn E
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5843 - 5843
Abstract Introduction: The development of tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis of patients (pts) with chronic myeloid leukemia... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance
by Patel, Ami B and Pomicter, Anthony D and Yan, Dongqing and Eiring, Anna M and Franzini, Anca and O'Hare, Thomas and Deininger, Michael W
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2641 - 2641
Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis. FLT3 internal tandem duplications (ITDs) are found in ~30%... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.